Dopamine vs noradrenaline: Inverted-U effects and ADHD theories

Australian and New Zealand Journal of Psychiatry

Volumn 43, Issue 2, 2009, Pages 101-108

  Levy, Florence ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Attention deficit hyperactivity disorder; Dopamine; Inverted U; Noradrenaline; Working memory

Indexed keywords

ALPHA 2A ADRENERGIC RECEPTOR; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; BETA 1 ADRENERGIC RECEPTOR; CATECHOLAMINE; DOPAMINE; DOPAMINE 1 RECEPTOR; GUANFACINE; METHIONINE; NORADRENALIN; PLACEBO; VALINE;

ACUTE STRESS; ATTENTION DEFICIT DISORDER; BRAIN DEPTH STIMULATION; CLINICAL TRIAL; COGNITION; DOSE RESPONSE; DRUG MECHANISM; GENETIC POLYMORPHISM; HEREDITY; HUMAN; NERVE CELL NETWORK; NERVE EXCITABILITY; NERVE POTENTIAL; NONHUMAN; NORADRENALIN RELEASE; PATHOGENESIS; PERCEPTIVE THRESHOLD; POSTTRAUMATIC STRESS DISORDER; PREFRONTAL CORTEX; REVIEW; SEDATION; SENSORIMOTOR FUNCTION; SPATIAL MEMORY; SYNAPTIC TRANSMISSION; TREATMENT RESPONSE; WORKING MEMORY;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC UPTAKE INHIBITORS; ALLELES; ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CATECHOL O-METHYLTRANSFERASE; DOPAMINE; GUANFACINE; HUMANS; MEMORY, SHORT-TERM; NERVE NET; NOREPINEPHRINE; POLYMORPHISM, GENETIC; PREFRONTAL CORTEX; PROPYLAMINES; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, DOPAMINE D4; SPACE PERCEPTION; THALAMUS;

EID: 58849144237     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1080/00048670802607238     Document Type: Review

References (62)

1. Biederman, J., Baldessarini, RJ, Wright, W., Knee, D. and Harmatz, JS. (1985) A double-blind placebo controlled study of desipramine in the treatment of ADD. J Am Acad Child Adolesc Psychiatry, 28, pp. 777-784.
2. Zametkin, AJ, Rappaport, JL, Murphy, DL, Linnoila, M. and Ishmond, D. Treatment of hyperactive children with monoamine oxidase inhibitors. 1. Clinical efficacy. Arch Gen Psychiatry, 42, pp. 962-966.
3. Levy, F. (1991) The dopamine theory of attention deficit hyperactivity disorder (ADHD). Aust N Z J Psychiatry, 25, pp. 277-283.
4. Coyle, J. and Snyder, S. (1969) Catecholamine uptake by synaptosomes in homogenates of rat brain: Stereospecificity in different areas. J Pharmacol Exp Ther, 170, pp. 221-231.
5. Taylor, M. and Snyder, SH. (1970) Amphetamine: Differentiation by d- and l- isomers of behaviour involving brain norepinephrine or dopamine. Science, 168, pp. 1487-1488.
6. Harris, JE and Balsessarini, R. (1973) Uptake of [3H]-catecholamines by homogenates of rat corpus striatum and cerebral cortex: Effects of amphetamine analogues. Neuropsychopharmacology, 12, pp. 669-679.
7. Levy, F. and Hobbes, G. (1988) The action of stimulant medication in attention deficit disorder with hyperactivity: Dopaminergic, noradrenergic, or both?. J Am Acad Child Adolesc Psychiatry, 27, pp. 802-805.
8. Sprague, RL and Sleator, EK. (1977) Methylphenidate in hyperkinetic children: Differences in dose effects on learning and social behavior. Science, 198, pp. 1274-1276.
9. Grossberg, S. (1999) Neural models of normal and abnormal behavior: What do schizophrenia, parkinsonism, and attention deficit disorder, and depression have in common?. Prog Brain Res, 121, pp. 375-406.
10. Evans, SW and Pelham, WE. (1991) Psychostimulant effects on academic and behavioral measures for ADHD junior high school students in a lecture format classroom. J Abnorm Child Psychol, 19, pp. 537-552.
11. Douglas, VI, Barr, RG, Desilets, J. and Sherman, E. (1994) Do high doses of stimulants impair flexible thinking in Attention-deficit hyperactivity disorder?. J Am Acad Child Adolesc Psychiatry, 34, pp. 877-885.
12. Solanto, MV and Wender, EH. (1989) Neuropharmacological basis of stimulant drug action in attention deficit disorder with hyperactivity. Psychol Bull, 26, pp. 897-902.
13. Tannock, R. and Schachar, R. (1992) Methylphenidate and cognitive perserveration in hyperactive children. J Child Psychol Psychiatry, 33, pp. 1217-1228.
14. Arnsten, AFT. (2007) Catecholamine and second messenger influences on prefrontal cortical networks of "representational knowledge": a rational bridge between genetics and the symptoms of mental illness. Cereb Cortex, 17, pp. i6-i15.
15. Goldman-Rakic, PS. (1995) Cellular basis of working memory. Neuron, 14, pp. 477-485.
16. Brozoski, T., Brown, RM, Rosvold, HE and Goldman, PS. (1979) Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science, 205, pp. 929-931.
17. Arnsten, AFT. (2006) Stimulants: Therapeutic actions in ADHD. Neuropsychopharmacology, 31, pp. 2376-2383.
18. Williams, GV and Goldman-Rakic, PS. (1995) Blockade of dopamine D1 receptors enhances memory fields of prefrontal neurons in primate cerebral cortex. Nature, 376, pp. 572-575.
19. Vijayraghavan, S., Wang, M., Birnbaum, SG, Williams, GV and Arnsten, AF. (2007) Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory. Nat Neurosci, 10, pp. 376-384.
20. Goldman-Rakic, PS. (1987) Handbook of physiology: The nervous system. Higher functions of the brain, pp. 373-417. American Physiological Society, Bethesda, MD
21. Arnsten, AFT and Goldman-Rakic, PS. (1985) Alpha-2 adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged nonhuman primates. Science, 230, pp. 1273-1276.
22. Arnsten, AFT and Robbins, TW. (2002) Neurochemical modulation of prefrontal cortical function in humans and animals. Principles of frontal lobe function, pp. 51-84. Oxford University Press, New York
23. Arnsten, AFT and Li, B-M. (2005) Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions. Biol Psychiatry, 57, pp. 1377-1384.
24. Schultz, W. (1998) The phasic reward signal of primate dopamine neurons. Adv Pharmacol, 42, pp. 686-690.
25. Ramos, B., Stark, D., Verduzco, L., van Dyck, CH and Arnsten, AFT. (2006) Alpha-2A-adrenoreceptor stimulation improves prefrontal cortical regulation of behavior through inhibition of cAMP signalling in aging animals. Learn Mem, 13, pp. 770-776.
26. Casey, BJ, Castellanos, FX Giedd, JN et al. (1997) Implication of right frontostriatal circuitry in response inhibition and attention deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry, 36, pp. 374-383.
27. Giedd, JN, Castellanos, FX Casey, BJ et al. (1994) Quantitative morphology of the corpus callosum in attention deficit hyperactivity disorder. Am J Psychiatry, 51, pp. 665-669.
28. Castellanos, FX, Giedd, JN Marsh, WL et al. (1996) Quantitative brain magnetic resonance imaging in attention-deficit hyperactivity disorder. Arch Gen Psychiatry, 53, pp. 607-616.
29. Lewis, DA and Gonzalez-Burgos, G. (2008) Neuroplasticity of neocortical circuits in schizophrenia. Neuropsychopharmacol Rev, 33, pp. 141-165.
30. Lewis, DA and Gonzalez-Burgos, G. (2006) Physiologically based treatment interventions in schizophrenia. Nat Med, 12, pp. 1016-1022.
31. Gonzalez-Burgos, G., Kroner, S. Krimer, LS et al. (2002) Dopamine modulation of neuronal function in the monkey prefrontal cortex. Physiol Behav, 77, pp. 537-543.
32. Sawaguchi, T. (2001) The effects of dopamine and its antagonists on directional delay-period activity of prefrontal neurons in monkeys during an oculomotor delayed-response task. Neurosci Res, 41, pp. 115-128.
33. Williams, GV and Goldman-Rakic, PS. (1995) Modulation of memory fields by dopamine Dl receptors in prefrontal cortex. Nature, 376, pp. 572-575.
34. Rotaru, DC, Lewis, DA and Gonzalez-Burgos, G. (2007) Dopamine D1 receptor activation regulates sodium channel-dependent EPSP amplification in rat prefrontal cortex pyramidal neurons. J Physiol, 581, pp. 981-1000.
35. Seamans, JK and Yang, CR. (2004) The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol, 74, pp. 1-58.
36. Castellanos, FX. (1997) Toward a pathophysiology of attention-deficit/ hyperactivity disorder. Clin Pediatr, 36, pp. 381-393.
37. Swanson, J. and Castellanos, FX. (1998) Biological bases of attention deficit hyperactivity disorder: Neuroanatomy, Genetics and Pathophysiology. NIH Consensus Conference on ADHD, NIH, Rockville, MD
38. Frank, MJ, Santamaria, A., O'Reilly, RC and Willcutt, E. (2007) Testing computational models of dopamine and noradrenaline dysfunction in attention/deficit hyperactivity disorder. Neuropsychopharmacology, 32, pp. 1583-1599.
39. Sonuga-Barke, EJS. (2003) The dual pathway model of AD/HD: An elaboration of neuro-developmental characteristics. Neurosci Biobehav Rev, 27, pp. 593-604.
40. Castellanos, FX, Sonuga-Barke, EJS, Scheres, A., Di Martino, A, Hyde, C. and Walters, JR. (2005) Varieties of attention-deficit/hyperactivity disorder-related intra-individual variability. Biol Psychiatry, 57, pp. 1416-1423.
41. Arnsten, AFT. (1998) Catecholamine modulation of prefrontal cortical cognitive function. Trends Cogn Sci, 2, pp. 436-447.
42. Arnsten, A., Steere, JC and Hunt, RD. (1996) The contribution of alpha sub2-noradrenergic mechanisms to prefrontal cortical cognitive function: potential significance for attention-deficit hyperactivity disorder. Arch Gen Psychiatry, 53, pp. 448-455.
43. Arnsten, AFT, Steere, JC, Jentsch, DJ and Li, BM. (1998) Noradrenergic influences on prefrontal cortical cognitive function: Opposing actions at post-junctional alpha1 versus alpha2- adrenergic receptors. Adv Pharmacol, 42, pp. 764-767.
44. Arnsten, AFT and Dudley, AG. (2005) Methylphenidate improves prefrontal cortical cognitive function through a2 adrenoreceptor and dopamine D1 receptor actions: Relevance to therapeutic effects in attention deficit hyperactivity disorder. Behav Brain Funct, 1, p. 2.
45. Berridge, CW, Devilbiss, DM Andrzejewski, ME et al. (2006) Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol Psychiatry, 60, pp. 1111-1120.
46. Arnsten, AF, Scahill, L. and Findling, RL. (2007) alpha-2-Adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: Emerging concepts from new data. J Child Adolesc Psychopharmacol, 17, pp. 393-406.
47. Biederman, J., Melmed, RD Patel, A. et al. (2008) A randomized, double-blind, placebo-controlled, study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatr, 121, pp. e73-e84.
48. Hazell, PL and Stuart, JE. (2003) A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. J Am Acad Child Adolesc Psychiatry, 42, pp. 886-894.
49. Martinussen, R., Hayden, J., Hogg-Johnson, S. and Tannock, J. (2005) A meta-analysis of working memory impairments in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry, 44, pp. 377-384.
50. Nigg, JT. (2005) Neuropsychologic theory and findings in attention/ deficit hyperactivity disorder: The state of the field and salient changes for the coming decade. Biol Psychiatry, 57, pp. 1424-1435.
51. Kerns, KA, McInerney, RJ and Wilde, J. (2001) Time reproduction, working memory, and behavioural inhibition in children with ADHD. Child Neuropsychol, 7, pp. 21-31.
52. Barnett, R., Maruff, P. Vance, A. et al. (2001) Abnormal executive function in attention deficit hyperactivity disorder: The effect of stimulant medication and age on spatial working memory. Psychol Med, 31, pp. 1107-1115.
53. Cook, EH, Stein, MA Krasowski, MD et al. (1995) Association of attention deficit disorder and the dopamine transporter gene. Am J Hum Genet, 56, pp. 993-998.
54. Gill, M., Daly, G., Heron, S., Hawl, Z. and Fitzgerald, M. (1997) Confirmation of association between attention deficit hyperactivity disorder and a dopamine transporter polymorphism. Mol Psychiatry, 2, pp. 311-313.
55. LaHoste, GJ, Swanson, JM Wigal, SB et al. (1996) Dopamine D4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder. Mol Psychiatry, 1, pp. 121-124.
56. Swanson, JM, Sunahara, GA Kennedy, JL et al. (1998) Association of the dopamine receptor D4 (DRD4) gene with a referred phenotype of attention deficit hyperactivity disorder (ADHD): A family-based approach. Mol Psychiatry, 3, pp. 38-41.
57. Smalley, SL, Bailey, JN Palmer, CG et al. (1998) Evidence that the dopamine D4 receptor is a susceptibility gene in attention deficit hyperactivity disorder. Mol Psychiatry, 3, pp. 427-430.
58. Comings, DE, Gade-Andavolu, R. Gonzalez, N. et al. (2000) Multivariate analysis of associations of 42 genes in ADHD, ODD and conduct disorder. Clin Genet, 58, pp. 31-40.
59. Faraone, SV, Perlis, RH Doyle, AE et al. (2005) Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry, 57, pp. 1313-1323.
60. Swanson, JM, Kinsbourne, M. Nigg, J. et al. (2007) Etiologic subtypes of attention-deficit/hyperactivity disorder: Brain imaging, molecular genetic and environmental factors and the dopamine hypothesis. Neuropsychol Rev, 17, pp. 39-59.
61. Levy, F. (2008) Pharmacological and therapeutic directions in ADHD: specificity in the PFC. Behav Brain Funct, 4, p. 12.
62. Cheon, K-A, Jun, J-Y and Cho, D-Y. (2008) Association of the catechol-O-methyltransferase polymorphism with methylphenidate response in a classroom setting in children with attention-deficit-hyperactivity disorder. Int Clin Psychopharmacol, 23, pp. 291-298.